- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark Pharmaceuticals Inc., USA has launched Clindamycin Phosphate Foam, 1%, which is therapeutically equivalent to Mylan Pharmaceuticals' Evoclin® Foam, 1%. The U.S. market for Evoclin® Foam, 1% reached annual sales of approximately $5.8 million according to IQVIA data for the year ending December 2024. This product launch expands Glenmark's portfolio in the dermatological space, providing opportunities for increased market share and revenue generation. As Glenmark continues to enhance its product offerings in a competitive landscape, investors should watch closely for potential growth stemming from this launch, which aligns with the company's strategic focus on therapeutic areas such as dermatology.